78 citations
,
January 2000 in “Gynecological Endocrinology” This study found that the progestins norgestimate and dienogest may help treat clinical hyperandrogeny in women by inhibiting skin 5 alpha-reductase activity with minimal androgenic potential.
63 citations
,
January 2012 in “The European Journal of Contraception & Reproductive Health Care” This study concluded that combined hormonal contraceptives containing desogestrel, drospirenone, or cyproterone acetate were associated with a higher risk of venous thromboembolism compared to those containing levonorgestrel.
46 citations
,
January 2007 in “The European Journal of Contraception & Reproductive Health Care” This review discusses the increased risk of venous thromboembolism associated with combined hormonal contraceptives, particularly noting higher risks with certain progestins like desogestrel, gestodene, and cyproterone acetate, but reports no new clinical findings.
22 citations
,
January 1995 in “The American Journal of Medicine” This article reviews the negative effects of androgenic disorders and highlights that newer oral contraceptives with less androgenic progestins may reduce these effects and improve compliance, but it reports no new results.
3 citations
,
July 2022 in “BJOG: An International Journal of Obstetrics and Gynaecology” This study reports that among young women, combined oral contraceptives containing chlormadinone, among others, are associated with an increased risk of venous thromboembolism compared to those containing levonorgestrel with low ethinylestradiol.